Following a full submission
AWMSG advice |
||
Status: Recommended | ||
Deferasirox (Exjade®) is recommended for use within NHS Wales for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older. It is also recommended for the treatment of chronic iron overload due to blood transfusions when desferrioxamine (DFO) therapy is contraindicated or inadequate in the following patient groups: - in patients with other anaemias, - in patients aged 2 to 5 years, - in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells). Deferasirox (Exjade®) is not suitable for shared care within NHS Wales. |
||
|
||
Medicine details |
||
Medicine name | deferasirox (Exjade®) | |
Formulation | dispersible tablet | |
Reference number | 105 | |
Indication | Treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older. Treatment of chronic iron overload due to blood transfusions when desferrioxamine therapy is contraindicated or inadequate in the following patient groups: patients with other anaemias; patients aged 2 to 5 years; patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) |
|
Company | Novartis Pharmaceuticals UK Ltd | |
BNF chapter | Nutrition & blood | |
Submission type | Full | |
Status | Recommended | |
Advice number | 0808 | |
NMG meeting date | 14/05/2008 | |
AWMSG meeting date | 13/06/2008 | |
Ratification by Welsh Government | 17/07/2008 | |
Date of issue | 18/07/2008 |